NXTC

NextCure, Inc.

NasdaqHealthcarePHARMACEUTICAL PREPARATIONS

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying$86.8k3 buys
Total selling$00 sales
Net open-market+$86.8kBuying minus selling
Active insiders2Distinct reporting owners

NXTC transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
ADAR1 Capital Management, LLC
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner buy
The buyer is a beneficial owner of more than 10% of the company.
SEC filing ↗
$62.9kView disclosure →
ADAR1 Capital Management, LLC
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner buy
The buyer is a beneficial owner of more than 10% of the company.
SEC filing ↗
$18.7kView disclosure →
ADAR1 Capital Management, LLC
10% owner
10%
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner buy
The buyer is a beneficial owner of more than 10% of the company.
SEC filing ↗
$5.22kView disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Nov 13, 2026

Open-market transaction mix · 3 transactions in the selected period
3 buys100%·0%0 sells

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026000$0$0$0
Nov 2026300$86,795.67$0+$86,795.67

Distinct insiders active

Reporting-owner CIKs by month · peak Nov 2026 (2)
Oct 2026: 0 insidersNov 2026: 2 insiders
Oct 2026Nov 2026
2distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
1 insider
Filing, role and holdings details

Filing-only signals

Deterministic matches in the selected period

Recent filing activity
Most recent 3 transactions on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy$62.9k
Largest sale—
10b5-1 detected0
Amended rows0

Transaction codes

By Form 4 transaction code in selected period
3transactionstxns
  • P · Open-market buys · dominant3 · 100%

Activity by reported role

A joint filing can contribute to multiple roles
10% owner3

Reported Holdings After

Separated by insider, security, and ownership type

Schneeberger DanielCommon Stock · Indirect · See Footnote
750k734kNov 5, 2026Nov 11, 2026
750,289Nov 11, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
2 active days
Oct 16 → Nov 16
LessMore

NextCure, Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at NextCure, Inc.?

ADAR1 Capital Management, LLC, Schneeberger Daniel.

When was the latest reported open-market purchase?

ADAR1 Capital Management, LLC reported a buy on Nov 11, 2026 valued at $62.9k. Read the SEC filing.

When was the latest reported open-market sale?

No code-S sale is available for this period.

What is the recent purchase and sale balance?

Net open-market buying in the selected period was $86,795.67.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.